Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SLC40A1 | Q9NP59 | 4/20 | 0.51 |
| ▸ | NFKBIA | P25963 | 2/20 | 0.51 |
| ▸ | RELA | Q04206 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | G6PD | P11413 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616424 | 0.78 | METAP2 (0.63) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL3947043 | 0.77 | SMN1; SMN2 (0.66) | ALDH1A1SLC40A1NFKBIARELAMEN1 | |
| SCHEMBL2530533 | 0.76 | LMNA (0.58) | ALDH1A1KMT2AGAAHPGDHTT | |
| SCHEMBL11593888 | 0.75 | KMT2A (0.57) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL17774583 | 0.73 | ALDH1A1 (0.50) | ALDH1A1SLC40A1NFKBIARELAGAA | |
| SCHEMBL31681419 | 0.73 | CA2 (0.60) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL3783806 | 0.72 | CA2 (0.66) | SLC40A1NFKBIARELAMEN1KMT2A | |
| SCHEMBL3842057 | 0.72 | CA12 (0.56) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL11509072 | 0.72 | MEN1 (0.56) | ALDH1A1SLC40A1NFKBIARELAMEN1 | |
| SCHEMBL6392497 | 0.72 | ALDH1A1 (0.75) | ALDH1A1MEN1KMT2AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511043-B2 | FXR modulators | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511043-B2 | FXR modulators | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511043-B2 | FXR modulators | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20040176426-A1 | FXR modulators | TULARIK, INC. | 2004-09-09 | — | — | US | disclosed |
| US-6777446-B2 | FARNESOID X RECEPTOR; TREATING DISEASES ASSOCIATED WITH ABNORMALLY HIGH OR LOW CHOLESTEROL LEVELS. | TULARIK, INC. | 2004-08-17 | — | — | US | disclosed |
| US-20020120137-A1 | Farnesoid X receptor; treating diseases associated with abnormally high or low cholesterol levels. | TULARIK INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002020463-A2 | FXR MODULATORS | TULARIK INC. (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120137-A1 | Farnesoid X receptor; treating diseases associated with abnormally high or low cholesterol levels. | NR1H4, NR1H2, NR1H3 | ALDH1A1 2422/4885SLC40A1 1223/4885NFKBIA 537/4885 |
| US-20040176426-A1 | FXR modulators | NR1H4, CYP7A1, CYP7B1 | ALDH1A1 1900/4885SLC40A1 1044/4885NFKBIA 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.